UTHSC In the Media


UT Health Science Center receives $12M grant to close rural health care gaps

In the Media Icon

The University of Tennessee Health Science Center will lead a four-year initiative aiming to close health care gaps for rural Tennesseans, funded by a $12 million grant from the Tennessee Department of Health.


UT Health Science Center receives $12M grant to close rural health care gaps

In the Media Icon

The University of Tennessee Health Science Center will lead a four-year initiative aiming to close health care gaps for rural Tennesseans, funded by a $12 million grant from the Tennessee Department of Health.


UT Health Science Center receives $12M grant to close rural health care gaps

In the Media Icon

The University of Tennessee Health Science Center will lead a four-year initiative aiming to close health care gaps for rural Tennesseans, funded by a $12 million grant from the Tennessee Department of Health.


UT Health Science Center receives $12M grant to close rural health care gaps

In the Media Icon

The University of Tennessee Health Science Center will lead a four-year initiative aiming to close health care gaps for rural Tennesseans, funded by a $12 million grant from the Tennessee Department of Health.


UT Health Science Center receives $12M grant to close rural health care gaps

In the Media Icon

The University of Tennessee Health Science Center will lead a four-year initiative aiming to close health care gaps for rural Tennesseans, funded by a $12 million grant from the Tennessee Department of Health.


Phase 2 Trial of ILYX-002 Shows Improved Conjunctival Staining in DED, with Penny Asbell, MD, MBA

In the Media Icon

Investigative topical immunomodulator ILYX-002 has proven its efficacy in treating moderate-to-severe dry eye disease (DED) by achieving its primary endpoint of total conjunctival staining in the recent ILYX-002-201 phase 2 trial.


Phase 2 Trial of ILYX-002 Shows Improved Conjunctival Staining in DED, with Penny Asbell, MD, MBA

In the Media Icon

Investigative topical immunomodulator ILYX-002 has proven its efficacy in treating moderate-to-severe dry eye disease (DED) by achieving its primary endpoint of total conjunctival staining in the recent ILYX-002-201 phase 2 trial.


Understanding Problematic Social Media Use in Adolescents

In the Media Icon

Social media provides benefits for teens, but there are also drawbacks.